BORSI, ENRICA
 Distribuzione geografica
Continente #
AS - Asia 3.386
NA - Nord America 2.863
EU - Europa 2.127
AF - Africa 213
SA - Sud America 171
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.766
Nazione #
US - Stati Uniti d'America 2.801
VN - Vietnam 1.098
CN - Cina 811
SG - Singapore 772
IT - Italia 681
GB - Regno Unito 338
DE - Germania 240
HK - Hong Kong 201
SE - Svezia 195
IN - India 141
FR - Francia 129
BR - Brasile 127
NL - Olanda 125
KR - Corea 109
RU - Federazione Russa 98
BD - Bangladesh 72
IE - Irlanda 70
CI - Costa d'Avorio 66
FI - Finlandia 48
ZA - Sudafrica 46
JP - Giappone 37
TG - Togo 36
SC - Seychelles 33
CA - Canada 31
BG - Bulgaria 26
CH - Svizzera 26
EE - Estonia 26
AT - Austria 23
PH - Filippine 23
PL - Polonia 22
MX - Messico 21
AR - Argentina 19
UA - Ucraina 18
NG - Nigeria 17
ES - Italia 16
IR - Iran 16
TH - Thailandia 16
BE - Belgio 14
TW - Taiwan 14
ID - Indonesia 12
IQ - Iraq 12
JO - Giordania 9
CO - Colombia 7
EC - Ecuador 7
RO - Romania 7
SA - Arabia Saudita 7
TR - Turchia 6
CZ - Repubblica Ceca 5
DZ - Algeria 5
LT - Lituania 5
UZ - Uzbekistan 5
AU - Australia 4
CY - Cipro 4
GR - Grecia 4
VE - Venezuela 4
CL - Cile 3
GT - Guatemala 3
PK - Pakistan 3
PT - Portogallo 3
AE - Emirati Arabi Uniti 2
LB - Libano 2
MA - Marocco 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
RS - Serbia 2
SV - El Salvador 2
TN - Tunisia 2
AO - Angola 1
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
GH - Ghana 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
NC - Nuova Caledonia 1
NO - Norvegia 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PY - Paraguay 1
QA - Qatar 1
TT - Trinidad e Tobago 1
TZ - Tanzania 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZW - Zimbabwe 1
Totale 8.766
Città #
Singapore 534
Ashburn 368
Ho Chi Minh City 313
Southend 284
Chandler 262
Hanoi 241
Hefei 218
Fairfield 204
Hong Kong 195
San Jose 185
Bologna 173
Ann Arbor 108
Seoul 104
Beijing 93
Dallas 93
Wilmington 89
Houston 85
Woodbridge 83
Seattle 79
New York 74
Dublin 70
Princeton 70
Cambridge 68
Abidjan 66
Santa Clara 62
Boardman 54
Los Angeles 53
Lauterbourg 50
Dong Ket 45
Milan 45
Haiphong 39
Lomé 36
Helsinki 34
Hyderabad 33
Munich 32
Nanjing 32
Tokyo 31
Westminster 28
Fabriano 27
Padova 26
Sofia 25
Bremen 24
Frankfurt am Main 24
Berlin 23
São Paulo 23
Council Bluffs 22
Amsterdam 21
Bengaluru 21
Da Nang 21
Rome 21
Guangzhou 20
Redondo Beach 20
Salsomaggiore Terme 20
Bern 19
Buffalo 19
Redmond 19
Biên Hòa 18
Jinan 17
Turin 17
Vienna 16
Can Tho 15
Warsaw 15
Abeokuta 14
Ha Long 14
Nanchang 14
Saint Petersburg 14
Brussels 13
Medford 13
Quận Bình Thạnh 13
Shenyang 13
Chicago 12
Johannesburg 12
London 12
Shanghai 12
Thái Nguyên 12
Toronto 12
Washington 12
Falkenstein 11
Hebei 11
Lappeenranta 11
Ninh Bình 11
Redwood City 11
Tianjin 11
Changsha 10
Naples 10
Nuremberg 10
Quận Một 10
Amman 9
Falls Church 9
Florence 9
Mondolfo 9
Wuhan 9
Brooklyn 8
Hải Dương 8
Paris 8
Tongling 8
Yubileyny 8
Zhengzhou 8
Bến Tre 7
Catania 7
Totale 5.531
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 711
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles 320
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 270
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 233
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 230
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 220
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 210
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 205
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 204
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 203
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 199
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 198
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 197
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 189
Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia 187
Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor 185
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 184
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 178
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 177
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 174
Cap dependent translation contributes to resistance of myeloma cells to bortezomib 173
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 171
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 168
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 166
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 166
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 163
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 163
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 155
A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies 154
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 154
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 153
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 153
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 150
Relative role ofAPCandMUTYHmutations in the pathogenesis of familial adenomatous polyposis 150
Analysis of mismatch repair gene mutations in Turkish HNPCC patients 146
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 141
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 141
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 139
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma 135
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 132
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 131
Italian cancer figures, report 2012: Cancer in children and adolescents. 122
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 109
AIRTUM numbers: 200,000 young Italians live with cancer 101
[Italian cancer figures, report 2010: Cancer prevalence in Italy. Patients living with cancer, long-term survivors and cured patients]. 100
[Italian cancer figures, report 2011: Survival of cancer patients in Italy]. 99
null 98
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 92
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 87
Loss of nuclear beta catenin, following chibby enforced expression, activates endoplasmic reticulum stress in cells expressing the BCR-ABL1 fusion gene of chronic myeloid leukemia 84
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 79
Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma 68
Totale 8.917
Categoria #
all - tutte 23.551
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.551


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021147 0 0 0 0 0 0 0 0 0 0 0 147
2021/2022742 32 36 41 48 65 41 20 41 42 103 121 152
2022/20231.009 80 133 43 153 79 83 30 47 144 57 81 79
2023/2024450 32 44 46 37 30 86 26 84 12 13 24 16
2024/20251.293 81 130 105 111 119 56 98 49 34 131 122 257
2025/20263.995 346 854 291 291 349 145 313 149 691 243 184 139
Totale 8.917